drugset / Trial / NCT00616733
12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a 12-week study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of oral CS-0777 in patients with Multiple Sclerosis.
Timeline
- Start
- 2008-03
- Primary completion
- 2010-09
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS-0777 | Unknown | 0.1 mg | Oral |
| Subject | CS-0777 | Unknown | 0.3 mg | Oral |
| Subject | CS-0777 | Unknown | 0.6 mg | Oral |